Cargando…
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409093/ https://www.ncbi.nlm.nih.gov/pubmed/34480862 http://dx.doi.org/10.1016/S2213-2600(21)00358-1 |
| _version_ | 1783746928735944704 |
|---|---|
| author | Kalil, Andre C Stebbing, Justin |
| author_facet | Kalil, Andre C Stebbing, Justin |
| author_sort | Kalil, Andre C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8409093 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84090932021-09-01 Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial Kalil, Andre C Stebbing, Justin Lancet Respir Med Comment Elsevier Ltd. 2021-12 2021-09-01 /pmc/articles/PMC8409093/ /pubmed/34480862 http://dx.doi.org/10.1016/S2213-2600(21)00358-1 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Kalil, Andre C Stebbing, Justin Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title | Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title_full | Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title_fullStr | Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title_full_unstemmed | Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title_short | Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial |
| title_sort | baricitinib: the first immunomodulatory treatment to reduce covid-19 mortality in a placebo-controlled trial |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409093/ https://www.ncbi.nlm.nih.gov/pubmed/34480862 http://dx.doi.org/10.1016/S2213-2600(21)00358-1 |
| work_keys_str_mv | AT kalilandrec baricitinibthefirstimmunomodulatorytreatmenttoreducecovid19mortalityinaplacebocontrolledtrial AT stebbingjustin baricitinibthefirstimmunomodulatorytreatmenttoreducecovid19mortalityinaplacebocontrolledtrial |